Marinus Pharma (MRNS) Reports In-Line Q4 EPS

Marinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $3.46 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08
• Paramount Global (PARA) Tops Q2 EPS by 480c